| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Parkinson's Disease | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Parkinson Disease | |||||
| Parkinsonian Disorders | |||||
| 3 | More general conditions related to this trial | ||||
| Basal Ganglia Diseases | |||||
| Brain Diseases | |||||
| Central Nervous System Diseases | |||||
| Movement Disorders | |||||
| Nervous System Diseases | |||||
| Neurodegenerative Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| apomorphine | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anti-Dyskinesia Agents | |||||
| Antiparkinson Agents | |||||
| Central Nervous System Agents | |||||
| Dopamine Agents | |||||
| Dopamine Agonists | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Oregon Health and Science University | |||||
| National Institute of Neurological Disorders and Stroke (NINDS) | |||||
|
